Abstract
Rationale exists for combined treatment with immune checkpoint inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors in a variety of solid tumours. This study aimed to investigate the safety and antitumour effects of pamiparib, an oral PARP 1/2 inhibitor, combined with tislelizumab, a humanised anti-PD-1 monoclonal antibody, in patients with advanced solid tumours and to determine the optimum doses for further evaluation. We did a multicentre, open-label, phase 1a/b study at five academic sites or community oncology centres in Australia. We recruited adults (aged ≥18 years) with advanced solid tumours who had received one or more previous lines of therapy, with an Eastern Cooperative Oncology Group performance score of 1 or less, and a life expectancy of 12 weeks or more. Patients were enrolled into one of five dose-escalation cohorts, with dose-escalation done in a 3 + 3 design. Cohorts 1-3 received intravenous tislelizumab 2 mg/kg every 3 weeks plus 20, 40, or 60 mg oral pamiparib twice daily, respectively; cohorts 4 and 5 received 200 mg intravenous tislelizumab every 3 weeks plus 40 or 60 mg oral pamiparib twice daily, respectively. The primary endpoints of the phase 1a dose-escalation part of the study were safety ...Continue Reading
References
Aug 18, 2006·Seminars in Cancer Biology·Stephan Gasser, David Raulet
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Oct 7, 2008·Oncogene·N Nausch, A Cerwenka
Jan 29, 2011·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gordon John Sampson RustinUNKNOWN Gynecological Cancer Intergroup
Mar 15, 2015·Science·Naiyer A RizviTimothy A Chan
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberMary L Disis
Jun 7, 2015·Biochemical and Biophysical Research Communications·Jing HuangMichael S Goldberg
Feb 11, 2016·International Journal of Molecular Sciences·Paul H Hayashi
Feb 13, 2016·Oncotarget·Kyle C StricklandPanagiotis A Konstantinopoulos
Jul 9, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roman M ChabanonSophie Postel-Vinay
Oct 13, 2016·Drug Design, Development and Therapy·Xi ZhangJinghua Li
Feb 9, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shiping JiaoMien-Chie Hung
Sep 17, 2017·Lancet·Robert L ColemanUNKNOWN ARIEL3 investigators
Apr 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kent W Mouw, Alan D D'Andrea
Apr 25, 2018·Cancer Immunology, Immunotherapy : CII·Tong ZhangKang Li
Oct 24, 2018·Seminars in Oncology·Hammad ShafqatAmy Sion
Jul 1, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B A G HaanenUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Citations
Jan 25, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eileen M O'ReillyDavid P Kelsen
Jun 13, 2020·Cancers·Florent Peyraud, Antoine Italiano
Mar 19, 2020·Drugs·Arnold Lee, Susan J Keam
Jun 13, 2020·Frontiers in Pharmacology·Jian-Ye ZhangLi-Wu Fu
Aug 14, 2020·Journal for Immunotherapy of Cancer·Pedro BarataOliver Sartor
Sep 5, 2020·Nature Reviews. Drug Discovery·Nicola J Curtin, Csaba Szabo
Oct 6, 2020·Frontiers in Cell and Developmental Biology·Maddison RoseEmma Bolderson
Dec 25, 2019·The Breast Journal·Hamdy A AzimLoay Kassem
May 28, 2020·Frontiers in Oncology·Praveen VikasRohan Garje
Jul 31, 2020·Signal Transduction and Targeted Therapy·Qiao WangXia Zhao
Nov 24, 2020·Frontiers in Medicine·Hong ZhengYunong Gao
Jun 25, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johann S BergholzJean J Zhao
Oct 27, 2020·Frontiers in Molecular Biosciences·Sangeeta KakotiAtsushi Shibata
Nov 7, 2020·Drug Discovery Today·Samridhi Lal, Timothy J Snape
Mar 28, 2021·Cancer Chemotherapy and Pharmacology·Song MuSrikumar Sahasranaman
May 5, 2021·Nature Medicine·Thomas PowlesDónal Landers
May 25, 2021·Frontiers in Oncology·Wei SunLin Yang
Jun 26, 2021·Journal of Experimental & Clinical Cancer Research : CR·Yali WangYanmei Zou
Jul 1, 2021·Immunotherapy·Nikolaos CharalampakisDimitrios Schizas
Jul 15, 2021·Cancer Treatment Reviews·Francesco PassigliaGiorgio Vittorio Scagliotti
Jul 22, 2021·Drugs·Anthony Markham
Jul 22, 2021·Nature Reviews. Clinical Oncology·Mariana Paes DiasJos Jonkers
Jul 25, 2021·Cancers·Liliana RaimundoLucília Saraiva
Aug 6, 2019·The Lancet Oncology·Ulrik Lassen
Aug 12, 2021·Nature Reviews. Cancer·Roman M ChabanonSophie Postel-Vinay
Dec 3, 2020·Journal of Medicinal Chemistry·Hexiang WangChangyou Zhou
Aug 28, 2021·Biomolecules·Mary-Ann XavierBart Cornelissen
Oct 29, 2021·Frontiers in Oncology·Kai ZimmerAndreas Seeber